Derakhshan Behrad, Chief Business Officer at Edgewise Therapeutics ($EWTX), made two open market sales of company shares over the past year, totaling about $61 thousand. His most recent sale occurred on August 12, 2025. These sales rank 10,167th among 11,678 insiders in our database, where the average is $8.6 million across 6.37 transactions. He reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 5781 | $0.00 | 26,136.0000 | 104,940,493 | 28.40% | 0.01% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 2491 | $13.39 | 23,645.0000 | 104,940,493 | 9.53% | 0.00% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Restricted Stock Units | 5781 | $0.00 | 17,344.0000 | 104,940,493 | 25.00% | 0.01% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | A | Restricted Stock Units | 30000 | $0.00 | 30,000.0000 | 104,940,493 | 9999.99% | 0.03% |
| Aug. 12, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | A | Stock Option (Right to Buy) | 180000 | $0.00 | 180,000.0000 | 104,940,493 | 9999.99% | 0.17% |
| May 1, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 5209 | $0.00 | 22,046.0000 | 95,130,053 | 30.94% | 0.01% |
| May 2, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 1691 | $16.45 | 20,355.0000 | 95,130,053 | 7.67% | 0.00% |
| May 1, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Restricted Stock Units | 5209 | $0.00 | 0.0000 | 95,130,053 | 100.00% | 0.01% |
| Feb. 5, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 10000 | $1.93 | 26,837.0000 | 92,414,626 | 59.39% | 0.01% |
| Feb. 5, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 10000 | $30.03 | 16,837.0000 | 92,414,626 | 37.26% | 0.01% |
| Feb. 5, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 92,929.0000 | 92,414,626 | 9.72% | 0.01% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 42068 | $1.93 | 57,189.0000 | 93,515,356 | 278.21% | 0.04% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 42068 | $29.03 | 15,121.0000 | 93,515,356 | 73.56% | 0.04% |
| Sept. 20, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Stock Option (Right to Buy) | 42068 | $0.00 | 102,949.0000 | 93,515,356 | 29.01% | 0.04% |
| Aug. 12, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | A | Stock Option (Right to Buy) | 138750 | $0.00 | 138,750.0000 | 93,515,356 | 9999.99% | 0.15% |
| Aug. 12, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | A | Restricted Stock Units | 23125 | $0.00 | 23,125.0000 | 93,515,356 | 9999.99% | 0.02% |
| May 1, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 5208 | $0.00 | 15,140.0000 | 87,567,307 | 52.44% | 0.01% |
| May 2, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 1718 | $18.91 | 13,422.0000 | 87,567,307 | 11.35% | 0.00% |
| May 1, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Restricted Stock Units | 5208 | $0.00 | 5,209.0000 | 87,567,307 | 50.00% | 0.01% |
| Feb. 7, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 600 | $1.93 | 7,620.0000 | 63,723,600 | 8.55% | 0.00% |
| Feb. 7, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 600 | $20.00 | 7,020.0000 | 63,723,600 | 7.87% | 0.00% |
| Feb. 8, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 4600 | $1.93 | 11,620.0000 | 63,723,600 | 65.53% | 0.01% |
| Feb. 8, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 4600 | $20.01 | 7,020.0000 | 63,723,600 | 39.59% | 0.01% |
| Feb. 9, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Common Stock | 4800 | $1.93 | 11,820.0000 | 63,723,600 | 68.38% | 0.01% |
| Feb. 9, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | S | Common Stock | 4800 | $20.04 | 7,020.0000 | 63,723,600 | 40.61% | 0.01% |
| Feb. 7, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Stock Option (Right to Buy) | 600 | $0.00 | 154,417.0000 | 63,723,600 | 0.39% | 0.00% |
| Feb. 8, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Stock Option (Right to Buy) | 4600 | $0.00 | 149,817.0000 | 63,723,600 | 2.98% | 0.01% |
| Feb. 9, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Derakhshan Behrad | Chief Business Officer | M | Stock Option (Right to Buy) | 4800 | $0.00 | 145,017.0000 | 63,723,600 | 3.20% | 0.01% |